Views & Analysis 'Free' pricing in the UK: the influence of NICE and NHS Engl... UK drug pricing: just how free is free pricing, these days?
Views & Analysis Is Europe ready for a single health technology assessment? The EU has unveiled plans for greater Health Technology Assessment harmonisation this week - and put the potential benefits for life sciences centre stage.
Views & Analysis Patient involvement in HTA Considering the essential role of patient experience in HTA and the role of pharma.
Views & Analysis The honest broker in market access Eric Low shares his views on why hurdles remain to new drug access.
Views & Analysis Mind the (implementation) gap Examining the true impact of a positive health technology assessment (HTA).
Views & Analysis Orphan drugs: overcoming barriers to market access What manufacturers should consider, after successfully overcoming any HTA hurdles, to achieve market access.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
